Key takeaways from Peter Attia’s article “Reducing cardiovascular risk: a playbook for lipid-lowering pharmacotherapy” (April 28, 2026):
• Focus on “how to treat,” not “whether to treat”: Evidence strongly supports pharmacologic LDL-C/apoB lowering for elevated levels to reduce ASCVD risk. The public debate should shift from statins’ existence to personalized, effective implementation.
• Mechanism-driven approach: All major lipid-lowering drugs (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors) primarily work by upregulating or modulating LDL receptors (LDLR) in the liver to clear atherogenic lipoproteins. Therapy should match the patient’s dominant cholesterol production/absorption pathway.
• Risk-stratified LDL/apoB targets: Therapy is tailored by risk category (e.g., lower targets for higher-risk patients, such as <50 mg/dL apoB or equivalent for high risk). Early and aggressive intervention is emphasized due to the cumulative, compounding benefits of long-term LDL-C reduction.
• Six-step playbook: The article outlines a practical decision framework covering:
1. Baseline measurements.
2. Identifying the patient’s primary pathway driving high LDL-C.
3. Selecting initial therapy (often statins as first-line for most, due to efficacy, cost, and availability).
4. Incorporating potent options like PCSK9 inhibitors (increasingly important for robust lowering).
5. Escalation/combination strategies when needed (e.g., adding ezetimibe or bempedoic acid).
6. Addressing real-world issues: statin intolerance (try alternatives or combinations), insurance/cost barriers, and ongoing monitoring.
• No one should die from preventable ASCVD: Modern tools enable very low levels safely for most. Combinations are often used when monotherapy is insufficient. Lifestyle remains foundational, but pharmacotherapy is a key tool in a proactive strategy.
The piece is a premium, detailed guide emphasizing personalized, biology-matched treatment over one-size-fits-all approaches. It aligns with Attia’s broader views on aggressive, early apoB/LDL reduction for longevity. For the full playbook and specifics, a subscription is required.
MGD’s 